# Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

> **NCT00662870** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1941 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Whooping Cough
- Polio
- Haemophilus Influenzae Type b

## Interventions

- **BIOLOGICAL:** DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)
- **BIOLOGICAL:** Pentacel: DTaP-IPV/Hib

## Key facts

- **NCT ID:** NCT00662870
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 1941 (ACTUAL)
- **Last updated:** 2012-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662870, "Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00662870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*